The content on this site is intended for healthcare professionals only
Prof Gabriel Hortobagyi talks to ecancer for the ESMO 2021 meeting about the overall survival results from the phase III MONALEESA study.
This study looked at the use of endocrine therapy with ribociclib in postmenopausal patients with HR positive and HER2 negative advanced breast cancer.
Prof Hortobagyi also reports that the advantage of the treatment seems to improve with time with the survival curves continuing to separate the longer the treatments go on.
Read more about this study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
ASCO 2023: Breast cancer research highlights
Breast and emerging indications for IORT
The advantages of IORT for early breast cancer treatment
Neo-adjuvant therapy for different cancers in the Philippines
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
